Stan Riddell, M.D. chairs the R&D Exec Committee for Lyell. In that capacity he directs the company’s strategic research and development efforts. Dr. Riddell is also a Member in the Program in Immunology at the Fred Hutchinson Cancer Research, Professor in the Department of Medicine at the University of Washington, Distinguished Affiliate Professor at the Technical University of Munich, and American Cancer Society Virginia Hobbs Charitable Trust Research Professor. His research program has focused on understanding the contributions of distinct human T cell subsets to protective immunity to tumors and on the development and clinical application of adoptive T cell therapy for cancer using unmodified and genetically modified antigen-specific T cells of defined compositions. The work has encompassed the discovery of target antigens for human cancer and evaluating the adoptive transfer of antigen-specific and genetically engineered T cells to treat human diseases. Dr. Riddell was the co-founder of ZetaRx Biosciences, Inc. and Juno Therapeutics, Inc. (acquired by Celgene Corp.).